| Objective: To investigate the efficacy and safety of Jiajianbaohe decoction combined with simvastatin on treatment of dyslipidemia in postmenopausal breast cancer patients with endocrine therapy in postmenopausal breast cancer patients,and to provide the basis for the clinical application of Jiajianbaohe decoction to ameliorate dyslipidemia with the therapy of adjuvant endocrine in postmenopausal breast cancer patients.Methods: In this study,84 cases of breast cancer with dyslipidemia in auxiliary endocrine therapy were selected,which met the inclusion standard,and the TCM syndrome types were in accordance with the distribution characteristics of phlegm and blood stasis syndrome.The patients were randomly divided into treatment group(n=42)and control group(n=42).The patients in the two groups continued to be treated with the third generation aromaticase inhibitor(AIS)assisted endocrine therapy(Letrozole 2.5mg qd).On this basis,the patients were treated with Jiajianbaohe decoction combined with simvastatin(treatment group)and simvastatin treatment(control group)for 4 weeks.Before and after treatment,the changes of blood lipid level,TCM syndrome score,KPS score,tumor markers,liver function,renal function,muscle enzyme,blood routine and so on were analyzed and compared.Results: 84 patients who met the inclusion criteria from February 2018 to August 2019 were selected in this study.One patient in the treatment group failed to take traditional Chinese medicine as required,and 2 patients in the control group lost follow-up and withdrew from the experiment.Finally,81 cases completed the experiment,41 cases in the treatment group and 40 cases in the control group.There were no significant differences in age,height,body weight,body mass index and tumor stage between the two groups(P>0.05).1.Before and after treatment,the level of blood lipid decreased in both the treatment group and the control group,in which TG,TC,LDL-C and Apo-B were significantly different before and after treatment(P<0.05).In the treatment group,TG,TC and LDL-C were better than that of the control group,and the total effective rate was also better than that of the control group(P<0.05).2.There was no significant difference between the score of syndrome between the treatment group and the control group(P>0.05).After 4 weeks of lipid-lowering treatment,the score of syndrome in treatment group was better than the control group(P<0.05).Comparing the improvement of TCM syndrome score,the excellence cases and effect cases in the treatment group were found to be superior to the control group,and the difference was statistically significant(P<0.05).3.There was no significant difference in KPS scores between the two groups before treatment(P>0.05).After 4 weeks of lipid-lowering treatment,the KPS scores of the two groups changed significantly compared with those before treatment(P<0.05).After treatment,the KPS score of the treatment group was increased,while that of the control group was decreased,and there was significant difference between the two groups(P<0.05).There was no significant difference in Ca-153,Ca-125,TK-1 between the treatment group and the control group before and after treatment.4.After treatment,there was no significant difference in the level of muscle enzyme,liver function,renal function and blood routine between the treatment group and the control group(P>0.05).Conclusion: 1.The combined treatment of Jiajiaobaohe decoction and simvastatin can improve dyslipidemia in patients with breast cancer assisted endocrine therapy.That can reduce blood lipid level of TG,TC and LDL-C better than simvastatin alone.2.Combined therapy alleviates TCM syndromes,improves patients’ living function(KPS score).That did not affect the level of tumor indexe,muscle enzyme,liver and kidney function and blood routine.It was safe for breast cancer patients with auxiliary endocrine therapy.3.Jiajiaobaohe decoction has clinical benefit in relieving dyslipidemia in patients with breast cancer assisted endocrine therapy.It has the value of promotion. |
PDF Full Text Request